当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.

Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.

Abstract：

:We identified dynein light chain 1 (DLC1) as a physiologic substrate of p21-activated kinase 1 (Pak1). Pak1-DLC1 interaction plays an essential role in cell survival, which depends on Pak1's phosphorylation of DLC1 on Ser88. Pak1 associates with the complex of DLC1 and BimL, a proapoptotic BH3-only protein, and phosphorylates both proteins. Phosphorylation of BimL by Pak1 prevents it from interacting with and inactivation of Bcl-2, an antiapoptotic protein. Overexpression of DLC1 but not DLC1-Ser88Ala mutant promotes cancerous properties of breast cancer cells. DLC1 protein level is elevated in more than 90% of human breast tumors. The regulation of cell survival functions by Pak1-DLC1 interaction represents a novel mechanism by which a signaling kinase might regulate the cancerous phenotypes.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Vadlamudi RK,Bagheri-Yarmand R,Yang Z,Balasenthil S,Nguyen D,Sahin AA,den Hollander P,Kumar R

doi

10.1016/j.ccr.2004.05.022

keywords:

subject

Has Abstract

pub_date

2004-06-01 00:00:00

pages

575-85

issue

6

eissn

1535-6108

issn

1878-3686

pii

S1535610804001473

journal_volume

5

pub_type

杂志文章

相关文献

CANCER CELL文献大全
  • A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

    abstract：:Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an integrated bioinformatics pipeline, we found that PTK2, encoding focal adhesion kinase (FAK), represents a candidate synthetic lethal gene with...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.01.009

    authors： Feng X,Arang N,Rigiracciolo DC,Lee JS,Yeerna H,Wang Z,Lubrano S,Kishore A,Pachter JA,König GM,Maggiolini M,Kostenis E,Schlaepfer DD,Tamayo P,Chen Q,Ruppin E,Gutkind JS

    更新日期：2019-03-18 00:00:00

  • VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

    abstract：:Oncolytic viruses designed to attack malignant cells can in addition infect and destroy tumor vascular endothelial cells. We show here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment is a consequence of VEGF-mediated suppression of the intrinsic antiviral response. VEGF/VEGFR2 sig...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.06.009

    authors： Arulanandam R,Batenchuk C,Angarita FA,Ottolino-Perry K,Cousineau S,Mottashed A,Burgess E,Falls TJ,De Silva N,Tsang J,Howe GA,Bourgeois-Daigneault MC,Conrad DP,Daneshmand M,Breitbach CJ,Kirn DH,Raptis L,Sad S,Atkins H

    更新日期：2015-08-10 00:00:00

  • Powering Tumor Metastasis with Recycled Fuel.

    abstract：:Receptor tyrosine kinase (RTK) recycling is of critical importance for RTK signaling and cancer, yet the process is poorly understood. In this issue, Ye et al. identify GOLM1 as a cargo adaptor that drives hepatocellular carcinoma metastasis by promoting EGFR recycling and provide insights into how this process is reg...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.08.014

    authors： Hung MC,Yang R,Sun Y

    更新日期：2016-09-12 00:00:00

  • A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

    abstract：:Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mT...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.01.014

    authors： Fan Q,Aksoy O,Wong RA,Ilkhanizadeh S,Novotny CJ,Gustafson WC,Truong AY,Cayanan G,Simonds EF,Haas-Kogan D,Phillips JJ,Nicolaides T,Okaniwa M,Shokat KM,Weiss WA

    更新日期：2017-03-13 00:00:00

  • Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

    abstract：:PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK an...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.08.017

    authors： Cheung LW,Yu S,Zhang D,Li J,Ng PK,Panupinthu N,Mitra S,Ju Z,Yu Q,Liang H,Hawke DH,Lu Y,Broaddus RR,Mills GB

    更新日期：2014-10-13 00:00:00

  • M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.

    abstract：:In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction nee...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2019.06.004

    authors： Srour N,Mersaoui SY,Richard S

    更新日期：2019-07-08 00:00:00

  • Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

    abstract：:Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion of pre-malignant cells via transcriptional silencing of proliferation-related genes due to decoration of their promoters with repressive trimethylated histone H3 lysine 9 (H3K9) marks. We show here that structurally distinct H3K9-active d...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.01.002

    authors： Yu Y,Schleich K,Yue B,Ji S,Lohneis P,Kemper K,Silvis MR,Qutob N,van Rooijen E,Werner-Klein M,Li L,Dhawan D,Meierjohann S,Reimann M,Elkahloun A,Treitschke S,Dörken B,Speck C,Mallette FA,Zon LI,Holmen SL,Peeper DS

    更新日期：2018-02-12 00:00:00

  • Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.

    abstract：:Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.10.008

    authors： Zhao W,Li J,Chen MM,Luo Y,Ju Z,Nesser NK,Johnson-Camacho K,Boniface CT,Lawrence Y,Pande NT,Davies MA,Herlyn M,Muranen T,Zervantonakis IK,von Euw E,Schultz A,Kumar SV,Korkut A,Spellman PT,Akbani R,Slamon DJ,Gray

    更新日期：2020-12-14 00:00:00

  • Twist1-induced invadopodia formation promotes tumor metastasis.

    abstract：:The Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, specialized membrane protrusions for extracellular matrix degradation. Twist1 induces PDGFRα expression, which in tu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.01.036

    authors： Eckert MA,Lwin TM,Chang AT,Kim J,Danis E,Ohno-Machado L,Yang J

    更新日期：2011-03-08 00:00:00

  • Long Noncoding RNAs in Cancer Pathways.

    abstract：:Genome-wide cancer mutation analyses are revealing an extensive landscape of functional mutations within the noncoding genome, with profound effects on the expression of long noncoding RNAs (lncRNAs). While the exquisite regulation of lncRNA transcription can provide signals of malignant transformation, we now underst...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2016.03.010

    authors： Schmitt AM,Chang HY

    更新日期：2016-04-11 00:00:00

  • Cancer's sweet tooth.

    abstract：:Even in the presence of an adequate oxygen supply, many tumors metabolize the majority of the glucose they take up through glycolysis. It has been a long-held belief that this glycolytic phenotype is due to cancer-specific defects in mitochondrial oxidative phosphorylation. In this issue of Cancer Cell, Fantin et al. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2006.05.012

    authors： Bui T,Thompson CB

    更新日期：2006-06-01 00:00:00

  • Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.

    abstract：:The TIGAR protein has antioxidant activity that supports intestinal tissue repair and adenoma development. Using a pancreatic ductal adenocarcinoma (PDAC) model, we show that reactive oxygen species (ROS) regulation by TIGAR supports premalignant tumor initiation while restricting metastasis. Increased ROS in PDAC cel...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.12.012

    authors： Cheung EC,DeNicola GM,Nixon C,Blyth K,Labuschagne CF,Tuveson DA,Vousden KH

    更新日期：2020-02-10 00:00:00

  • Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

    abstract：:We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G2 DNA damage checkpoint in both normal and ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.05.001

    authors： Fang Y,McGrail DJ,Sun C,Labrie M,Chen X,Zhang D,Ju Z,Vellano CP,Lu Y,Li Y,Jeong KJ,Ding Z,Liang J,Wang SW,Dai H,Lee S,Sahni N,Mercado-Uribe I,Kim TB,Chen K,Lin SY,Peng G,Westin SN,Liu J,O'Connor MJ,Yap T

    更新日期：2019-06-10 00:00:00

  • Radiotherapy complements immune checkpoint blockade.

    abstract：:Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2015.03.015

    authors： Ngiow SF,McArthur GA,Smyth MJ

    更新日期：2015-04-13 00:00:00

  • Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis.

    abstract：:How loss-of-function of GATA3 contributes to the development of breast cancer is poorly understood. Here, we report that GATA3 nucleates a transcription repression program composed of G9A and MTA3-, but not MTA1- or MTA2-, constituted NuRD complex. Genome-wide analysis of the GATA3/G9A/NuRD(MTA3) targets identified a ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.04.011

    authors： Si W,Huang W,Zheng Y,Yang Y,Liu X,Shan L,Zhou X,Wang Y,Su D,Gao J,Yan R,Han X,Li W,He L,Shi L,Xuan C,Liang J,Sun L,Wang Y,Shang Y

    更新日期：2015-06-08 00:00:00

  • No T without D3: a critical role for cyclin D3 in normal and malignant precursor T cells.

    abstract：:A definitive knockout reported in this issue of Cancer Cell by Sicinska et al. reveals an unsuspected role for cyclin D3 in normal T cell development and suggests new therapeutic possibilities in precursor T cell leukemia. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章,评审

    doi：10.1016/s1535-6108(03)00305-2

    authors： Weng AP,Aster JC

    更新日期：2003-12-01 00:00:00

  • Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.

    abstract：:It is believed that Mdm2 suppresses p53 in two ways: transcriptional inhibition by direct binding, and degradation via its E3 ligase activity. To study these functions physiologically, we generated mice bearing a single-residue substitution (C462A) abolishing the E3 function without affecting p53 binding. Unexpectedly...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2007.09.007

    authors： Itahana K,Mao H,Jin A,Itahana Y,Clegg HV,Lindström MS,Bhat KP,Godfrey VL,Evan GI,Zhang Y

    更新日期：2007-10-01 00:00:00

  • Chemokine to the rescue: interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer.

    abstract：:Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion....

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.11.012

    authors： Abraham RT

    更新日期：2012-12-11 00:00:00

  • Sumoylation pathway is required to maintain the basal breast cancer subtype.

    abstract：:The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2014.04.008

    authors： Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

    更新日期：2014-06-16 00:00:00

  • Species- and cell type-specific requirements for cellular transformation.

    abstract：:Recent evidence suggests that human cells require more genetic changes for neoplastic transformation than do their murine counterparts. However, a precise enumeration of these differences has never been undertaken. We have determined that perturbation of two signaling pathways-involving p53 and Raf-suffices for the tu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2004.07.009

    authors： Rangarajan A,Hong SJ,Gifford A,Weinberg RA

    更新日期：2004-08-01 00:00:00

  • Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.

    abstract：:Polymorphonuclear neutrophils (PMNs) are largely considered to foster cancer development despite wielding an arsenal of cytotoxic agents. Using a mouse model of PTEN-deficient uterine cancer, we describe a surprising inhibitory role for PMNs in epithelial carcinogenesis. By inducing tumor cell detachment from the base...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.11.005

    authors： Blaisdell A,Crequer A,Columbus D,Daikoku T,Mittal K,Dey SK,Erlebacher A

    更新日期：2015-12-14 00:00:00

  • Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.

    abstract：:A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma has been proposed. This process has been modeled in the mouse by activation of mutant Kras in pancreatic progenitor cells. In this issue of Cancer Cell, present a modification of their initial model by introducing a mut...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2005.04.025

    authors： Siveke JT,Schmid RM

    更新日期：2005-05-01 00:00:00

  • The ups and downs of SRC regulation: tumor suppression by Cbp.

    abstract：:Tight control of the tyrosine kinase activity of c-Src is critical for regulating its oncogenic potential. In a recent issue of Molecular Cell, Oneyama et al. (2008a) report that the membrane-bound adaptor protein Cbp (also known as PAG) can suppress c-Src-mediated cell transformation and tumorigenesis by binding and ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2008.05.011

    authors： Resh MD

    更新日期：2008-06-01 00:00:00

  • Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

    abstract：:We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 t...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.09.003

    authors： Zhang X,Zhao X,Fiskus W,Lin J,Lwin T,Rao R,Zhang Y,Chan JC,Fu K,Marquez VE,Chen-Kiang S,Moscinski LC,Seto E,Dalton WS,Wright KL,Sotomayor E,Bhalla K,Tao J

    更新日期：2012-10-16 00:00:00

  • Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma.

    abstract：:Obesity increases hepatocellular carcinoma (HCC) risks via unknown mediators. We report that hepatic unconventional prefoldin RPB5 interactor (URI) couples nutrient surpluses to inflammation and non-alcoholic steatohepatitis (NASH), a common cause of HCC. URI-induced DNA damage in hepatocytes triggers inflammation via...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.05.020

    authors： Gomes AL,Teijeiro A,Burén S,Tummala KS,Yilmaz M,Waisman A,Theurillat JP,Perna C,Djouder N

    更新日期：2016-07-11 00:00:00

  • Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

    abstract：:Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, ...

    journal_title：Cancer cell

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ccr.2011.11.023

    authors： Van der Veldt AA,Lubberink M,Bahce I,Walraven M,de Boer MP,Greuter HN,Hendrikse NH,Eriksson J,Windhorst AD,Postmus PE,Verheul HM,Serné EH,Lammertsma AA,Smit EF

    更新日期：2012-01-17 00:00:00

  • An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.

    abstract：:To define the mutation spectrum in non-Down syndrome acute megakaryoblastic leukemia (non-DS-AMKL), we performed transcriptome sequencing on diagnostic blasts from 14 pediatric patients and validated our findings in a recurrency/validation cohort consisting of 34 pediatric and 28 adult AMKL samples. Our analysis ident...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.10.007

    authors： Gruber TA,Larson Gedman A,Zhang J,Koss CS,Marada S,Ta HQ,Chen SC,Su X,Ogden SK,Dang J,Wu G,Gupta V,Andersson AK,Pounds S,Shi L,Easton J,Barbato MI,Mulder HL,Manne J,Wang J,Rusch M,Ranade S,Ganti R,Parker M,

    更新日期：2012-11-13 00:00:00

  • The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

    abstract：:The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest. This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2008.06.001

    authors： Bernassola F,Karin M,Ciechanover A,Melino G

    更新日期：2008-07-08 00:00:00

  • A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

    abstract：:Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.013

    authors： Vidal SJ,Rodriguez-Bravo V,Quinn SA,Rodriguez-Barrueco R,Lujambio A,Williams E,Sun X,de la Iglesia-Vicente J,Lee A,Readhead B,Chen X,Galsky M,Esteve B,Petrylak DP,Dudley JT,Rabadan R,Silva JM,Hoshida Y,Lowe SW,Cordo

    更新日期：2015-02-09 00:00:00

  • m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.

    abstract：:The dynamic and reversible N6-methyladenosine (m6A) RNA modification installed and erased by N6-methyltransferases and demethylases regulates gene expression and cell fate. We show that the m6A demethylase ALKBH5 is highly expressed in glioblastoma stem-like cells (GSCs). Silencing ALKBH5 suppresses the proliferation ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.02.013

    authors： Zhang S,Zhao BS,Zhou A,Lin K,Zheng S,Lu Z,Chen Y,Sulman EP,Xie K,Bögler O,Majumder S,He C,Huang S

    更新日期：2017-04-10 00:00:00